Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigative Site
mi
from
Sacramento, CA
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigative Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Santa Ana, CA
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Santa Ana, CA
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Santa Barbara, CA
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigative Site
mi
from
Santa Maria, CA
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigative Site
mi
from
Santa Maria, CA
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Colorado Springs, CO
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigative Site
mi
from
Fort Myers, FL
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigative Site
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Melbourne, FL
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Melbourne, FL
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Saint Petersburg, FL
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Tallahassee, FL
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Tallahassee, FL
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Shawnee Mission, KA
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Shawnee Mission, KA
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigative Site
mi
from
Wichita, KA
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigative Site
mi
from
Wichita, KA
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Paducah, KY
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Paducah, KY
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Las Vegas, NV
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Reno, NV
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Reno, NV
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Edison, NJ
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Edison, NJ
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Teaneck, NJ
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Teaneck, NJ
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Lynbrook, NY
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Lynbrook, NY
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Rochester, NY
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigative Site
mi
from
Charlotte, NC
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigative Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Camp Hill, PA
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Camp Hill, PA
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigative Site
mi
from
West Columbia, SC
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigative Site
mi
from
West Columbia, SC
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigative Site
mi
from
Abilene, TX
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigative Site
mi
from
Abilene, TX
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Houston, TX
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
San Antonio, TX
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
The Woodlands, TX
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
The Woodlands, TX
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigative Site
mi
from
Willow Park, TX
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigative Site
mi
from
Willow Park, TX
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Fairfax, VA
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Fairfax, VA
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Virginia Beach, VA
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Silverdale, WA
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Silverdale, WA
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Golden, CO
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Golden, CO
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Boynton Beach, FL
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Augusta, GA
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Augusta, GA
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Baltimore, MD
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Grand Rapids, MI
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Albuquerque, NM
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Kingston, PA
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Kingston, PA
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Columbus, OH
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Palm Desert, CA
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Palm Desert, CA
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
San Diego, CA
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigative Site
mi
from
Pensacola, FL
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigative Site
mi
from
Pensacola, FL
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigative Site
mi
from
Cleveland, OH
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigative Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Portland, OR
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Philadelphia, PA
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated:  12/31/1969
Opthea Investigational Site
mi
from
Hradec Králové,
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Enrolling
Updated: 12/31/1969
Opthea Investigational Site
mi
from
Hradec Králové,
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Joslin Diabetes Center
mi
from
Boston, MA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Joslin Diabetes Center
mi
from
Boston, MA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Retinal Diagnostic Center
mi
from
Campbell, CA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Retinal Diagnostic Center
mi
from
Campbell, CA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Atlantis Eye Care
mi
from
Huntington Beach, CA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Atlantis Eye Care
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Northern California Retina Vitreous Associates
mi
from
Mountain View, CA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Northern California Retina Vitreous Associates
mi
from
Mountain View, CA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Retinal Consultants of Southern California Medical Group, Inc.
mi
from
Westlake Village, CA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Retinal Consultants of Southern California Medical Group, Inc.
mi
from
Westlake Village, CA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
National Ophthalmic Research Institute
mi
from
Fort Myers, FL
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
National Ophthalmic Research Institute
mi
from
Fort Myers, FL
Click here to add this to my saved trials